Aethlon Medical Statistics
Total Valuation
Aethlon Medical has a market cap or net worth of $3.44 million. The enterprise value is -$3.17 million.
Important Dates
The last earnings date was Thursday, February 12, 2026, after market close.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aethlon Medical has 1.57 million shares outstanding. The number of shares has increased by 240.14% in one year.
| Current Share Class | 1.57M |
| Shares Outstanding | 1.57M |
| Shares Change (YoY) | +240.14% |
| Shares Change (QoQ) | +107.07% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 2.71% |
| Float | 1.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.68, with a Debt / Equity ratio of 0.06.
| Current Ratio | 5.68 |
| Quick Ratio | 5.53 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -725.59 |
Financial Efficiency
Return on equity (ROE) is -208.60% and return on invested capital (ROIC) is -75.22%.
| Return on Equity (ROE) | -208.60% |
| Return on Assets (ROA) | -62.88% |
| Return on Invested Capital (ROIC) | -75.22% |
| Return on Capital Employed (ROCE) | -107.87% |
| Weighted Average Cost of Capital (WACC) | 12.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.53% in the last 52 weeks. The beta is 1.65, so Aethlon Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.65 |
| 52-Week Price Change | -92.53% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 6.75 |
| Relative Strength Index (RSI) | 53.03 |
| Average Volume (20 Days) | 83,600 |
Short Selling Information
The latest short interest is 70,872, so 4.52% of the outstanding shares have been sold short.
| Short Interest | 70,872 |
| Short Previous Month | 86,540 |
| Short % of Shares Out | 4.52% |
| Short % of Float | 4.79% |
| Short Ratio (days to cover) | 0.91 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.33M |
| Pretax Income | -11.52M |
| Net Income | -11.52M |
| EBITDA | -7.01M |
| EBIT | -7.33M |
| Earnings Per Share (EPS) | -$28.51 |
Full Income StatementBalance Sheet
The company has $6.96 million in cash and $417,522 in debt, with a net cash position of $6.54 million or $4.17 per share.
| Cash & Cash Equivalents | 6.96M |
| Total Debt | 417,522 |
| Net Cash | 6.54M |
| Net Cash Per Share | $4.17 |
| Equity (Book Value) | 6.71M |
| Book Value Per Share | 6.90 |
| Working Capital | 5.88M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.92 million and capital expenditures $539, giving a free cash flow of -$6.92 million.
| Operating Cash Flow | -6.92M |
| Capital Expenditures | 539 |
| Depreciation & Amortization | 327,970 |
| Net Borrowing | n/a |
| Free Cash Flow | -6.92M |
| FCF Per Share | -$4.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aethlon Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -240.14% |
| Shareholder Yield | -240.14% |
| Earnings Yield | -341.54% |
| FCF Yield | -205.13% |
Analyst Forecast
The average price target for Aethlon Medical is $15.00, which is 584.93% higher than the current price. The consensus rating is "Hold".
| Price Target | $15.00 |
| Price Target Difference | 584.93% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -68.64% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 20, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Oct 20, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
